Idenix (IDIX) Enters License Agreement With GlaxoSmithKline For HIV Treatment IDX899
Tweet Send to a Friend
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and GlaxoSmithKline (NYSE: GSK) executed a license agreement granting GSK exclusive worldwide rights to IDX899.
This article: 105 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 105 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
